参考文献/References:
[1] 中华人民共和国国家统计局. 中国统计年鉴2019[M]. 北京:中国统计出版社,2019:37.
[2] Boyce B F,Xing L. Biology of rank,rank,and osteoprote-gerin [J]. Arthritis Res Ther,2007,9(1):1.
[3] Boyce B F,Xing L. Functions of RANKL/RANK/OPG in bone modeling and remodeling[J]. Arch Biochem Biophys,2008,473(2):139-146.
[4] Lacey D L,Boyle W J,Simonet W S,et al. Bench to bedside:elucidation of the OPG-RANK-RANKL pathway and the development of denosumab[J]. Nat Rev Drug Discov,2012,11(5):401-419.
[5] Kostenuik P J,Nguyen H Q,McCabe J,et al. Denosumab,a fully human monoclonal antibody to RANKL,inhibits bone resorption and increases BMD in knock-in mice that express chimeric(murine/human)RANKL[J]. J Bone Miner Res,2009,24(2):182-195.
[6] Cummings S R,San M J,McClung M R,et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis[J]. N Engl J Med,2009,361(8):756-765.
[7] Bilezikian J P,Lin C J F,Brown J P,et al. Long-term denosumab treatment restores cortical bone loss and reduces fracture risk at the forearm and humerus: analyses from the FREEDOM Extension cross-over group[J]. Osteoporosis,2019,30(9):1855-1864.
[8] Kendler D L,Chines A,Brandi M L,et al. The risk of subsequent osteoporotic fractures is decreased in subjects experiencing fracture while on denosumab:results from the FREEDOM and FREEDOM Extension studies[J]. Osteoporosis,2019,30(1):71-78.
[9] Shoback D,Rosen C J,Black D M,et al. Pharmacological management of osteoporosis in postmenopausal women:an endocrine society guideline update[J]. J Clin Endocrinol Metab,2020,105(3):587-594.
[10] Behanova M,Reichardt B,Stamm T A,et al. Treatment effects of bisphosphonates and denosumab on survival and refracture from real-world data of hip-fractured patients[J]. Calcif Tissue,2019,105(6):630-641.
[11] Gnant M,Pfeiler G,Dubsky P C,et al. Adjuvant denosumab in breast cancer(ABCSG-18):a multicentre,randomized,double-blind,placebo-controlled trial[J]. Lancet,2015,386(9992):433-443.
[12] Nakamura T,Matsumoto T,Sugimoto T,et al. Clinical trials express:fracture risk reduction with denosumab in Japanese postmenopausal women and men with osteoporosis:denosumab fracture intervention randomized placebo controlled trial(DIRECT) [J]. J Clin Endocrinol Metabolism,2014,99(7):2599-2607.
[13] Broadwell A,Chines A,Ebeling P R,et al. Denosumab safety and efficacy among participants in the FREEDOM extension study with mild to moderate chronic kidney disease[J]. J Clin Endocrinol Metab,2021,106(2):397-409.
[14] Otto S,Pautke C,Van W,et al. Medication-related osteonecrosis of the jawpPrevention,diagnosis and management in patients with cancer and bone metastases[J]. Cancer Treat Rev,2018,69(9):177-187.
[15] Fassio A,Adami G,Benini C,et al. Changes in Dkk-1,sclerostin,and RANKL serum levels following discontinuation of long-term denosumab treatment in postmenopausal women[J]. Bone,2019,123(6):191-195.
[16] Jahn R K,Wolfel EM,Jobke B,et al. Elevated bone hardness under denosumab treatment,with persisting lower osteocyte viability during discontinuation[J]. Front Endocrinol,2020,11(5):250.
[17] Niimi R,Kono T,Nishihara A,et al. Second rebound-associated vertebral fractures after denosumab discontinuation[J]. Arch Osteoporos,2020,15(1):7.
[18] Adami S,Libanati C,Boonen S,et al. Denosumab treatment in postmenopausal women with osteoporosis does not interfere with fracture-healing:results from the FREEDOM trial[J]. J Bone Joint Surg Am,2012,94(23):2113-2119.